Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AVMXY NASDAQ:CLLS OTCMKTS:OSIR NASDAQ:PRTO NASDAQ:RUBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVMXYAVITA MED LTD/S$7.89$7.89$1.06▼$8.58$651.87M1.28183,275 shsN/ACLLSCellectis$1.59-3.6%$1.49$1.10▼$2.43$88.38M2.91143,724 shs17,240 shsOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/APRTOProteon Therapeutics$3.05-2.2%$19.37$0.22▼$3.94$67.65M0.61.11 million shs118,209 shsRUBYRubius Therapeutics$0.06$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,858 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVMXYAVITA MED LTD/S0.00%0.00%0.00%0.00%0.00%CLLSCellectis0.00%+0.32%+16.33%+10.42%-18.46%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%PRTOProteon Therapeutics-2.24%+5.54%-7.29%-21.99%+43.19%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVMXYAVITA MED LTD/SN/AN/AN/AN/AN/AN/AN/AN/ACLLSCellectis3.4357 of 5 stars3.54.00.00.03.32.50.6OSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVMXYAVITA MED LTD/S 0.00N/AN/AN/ACLLSCellectis 3.00Buy$4.00151.57% UpsideOSIROsiris Therapeutics 0.00N/AN/AN/APRTOProteon Therapeutics 0.00N/AN/AN/ARUBYRubius Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CLLS, RUBY, OSIR, AVMXY, and PRTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVMXYAVITA MED LTD/S$5.51M118.31N/AN/A$0.26 per share30.35CLLSCellectis$49.22M1.80N/AN/A$2.36 per share0.67OSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/A($0.06) per shareN/ARUBYRubius TherapeuticsN/AN/AN/AN/A$0.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVMXYAVITA MED LTD/S-$24.75M-$0.39N/A∞N/AN/AN/AN/AN/ACLLSCellectis-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)OSIROsiris TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/APRTOProteon Therapeutics-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/ARUBYRubius Therapeutics-$179.67MN/A0.00∞N/AN/AN/AN/AN/ALatest CLLS, RUBY, OSIR, AVMXY, and PRTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025N/ACLLSCellectis-$0.15N/AN/AN/A$10.07 millionN/A5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVMXYAVITA MED LTD/SN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVMXYAVITA MED LTD/SN/A5.505.33CLLSCellectis0.441.671.67OSIROsiris TherapeuticsN/AN/AN/APRTOProteon TherapeuticsN/A5.985.98RUBYRubius TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVMXYAVITA MED LTD/S0.01%CLLSCellectis63.90%OSIROsiris Therapeutics0.28%PRTOProteon Therapeutics23.03%RUBYRubius TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAVMXYAVITA MED LTD/SN/ACLLSCellectis16.41%OSIROsiris Therapeutics43.40%PRTOProteon Therapeutics45.70%RUBYRubius Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVMXYAVITA MED LTD/S5582.62 millionN/ANot OptionableCLLSCellectis29055.58 million46.46 millionOptionableOSIROsiris Therapeutics34234.53 millionN/ANot OptionablePRTOProteon Therapeutics1722.18 millionN/ANot OptionableRUBYRubius Therapeutics690.48 million85.69 millionNot OptionableCLLS, RUBY, OSIR, AVMXY, and PRTO HeadlinesRecent News About These CompaniesHere’s how to get the El Rubius skin in Fortnite with the most adorable back blingSeptember 17, 2024 | oneesports.ggOAll About the Rubius Skin in FortniteSeptember 17, 2024 | esports.netETwitch star Rubius is giving Fortnite players a good reason to buy his skinSeptember 17, 2024 | dexerto.comDFortnite Fans Only Want One Thing from the Rubius SkinSeptember 17, 2024 | msn.comHow to get the Rubius Icon Series skin in FortniteSeptember 16, 2024 | dexerto.comDHow to Get the Exclusive Rubius Fortnite DropSeptember 15, 2024 | msn.comRubius teases potential Fortnite Icon Series skin in cryptic YouTube videoAugust 4, 2024 | dexerto.comD‘Expats’ Star Ruby Ruiz to Lead James J. Robinson’s Directorial Debut ‘First Light’ (EXCLUSIVE)April 26, 2024 | yahoo.comVacant Rubius property generating interest after 1 year on marketApril 18, 2024 | pbn.comPSensorium Therapeutics Appoints Sam Rasty as Chief Business OfficerApril 17, 2024 | citizentribune.comCVacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'March 11, 2024 | bizjournals.comRubius Therapeutics Inc RUBYNovember 5, 2023 | morningstar.comM‘Like playing the lottery’: Laid-off life sciences workers give a snapshot of a cooling-down sectorOctober 16, 2023 | bostonglobe.comBRuby Dunne Biography & MoviesSeptember 22, 2023 | tribute.caTParenting Vlogger Ruby Franke Held Without Bail on Child Abuse ChargesSeptember 14, 2023 | oxygen.comOYouTuber mom Ruby Franke arrested and charged in child abuse investigation: What to knowSeptember 8, 2023 | today.comTRuby GonzalesAugust 21, 2023 | dailynews.comDRUBY - Rubius Therapeutics, Inc.August 2, 2023 | uk.finance.yahoo.comNorth American Morning Briefing: Alphabet, -2-July 25, 2023 | morningstar.comMRuby Rivera, 23ABCJune 30, 2023 | turnto23.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLLS, RUBY, OSIR, AVMXY, and PRTO Company DescriptionsAVITA MED LTD/S OTCMKTS:AVMXYAvita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.Cellectis NASDAQ:CLLS$1.59 -0.06 (-3.64%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.55 -0.04 (-2.52%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Osiris Therapeutics OTCMKTS:OSIR$18.99 0.00 (0.00%) As of 04/17/2019Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Proteon Therapeutics NASDAQ:PRTOProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.Rubius Therapeutics NASDAQ:RUBYRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Conagra at Rock Bottom: 7% Yield & Turnaround Poised Delta Air Lines Could Reach New Highs in 2025—And Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
